Latest Production News

Findi Limited surged revenue by 36% to $83 million for FY26 but posted a hefty $52.6 million net loss, weighed down by integration costs and capital delays. The company completed a major consolidation of its Indian financial infrastructure assets and secured $25 million in fresh capital to support growth and liquidity.

Bass Oil Limited offers up to 24 million free attaching options to recent placement participants, alongside nearly 8 million options to its lead manager PAC Partners, with no new funds raised from the options issue.

Amplia Therapeutics reported encouraging mature data from its ACCENT pancreatic cancer trial showing improved survival and response rates with narmafotinib. The company raised $27.5 million to fund development and manufacturing scale-up, while discontinuing a parallel trial due to chemotherapy toxicity.

Burger Fuel Group reported a 91.8% surge in net profit to NZD 1.97 million for FY26, driven by sales growth, reduced legal costs, and a one-off store sale gain, despite geopolitical headwinds in the Middle East.

Papyrus Australia has secured a key milestone under its TBS Mining Contract by executing a board production deal with a Vietnam manufacturer, while raising $325,000 to support commercial scale-up and facility establishment.

Acrux has locked in a milestone-based licensing agreement worth up to AUD 5.4 million for Lenzetto®, targeting the Australian menopause therapy market with regulatory and commercial milestones tied to TGA approval and sales performance.

Green Technology Metals (ASX: GT1) secured $1.87 million from its recent entitlement offer, with underwriters stepping in to cover a $2.13 million shortfall. The capital raise supports ongoing development of its Ontario lithium project.

New Talisman Gold Mines boosted revenue by 121% to NZ$53,000 but posted a $2.26 million net loss as it commissioned a processing plant and secured key commercial agreements.

Killi Resources has significantly extended the King Louie Breccia gold-copper-molybdenum anomaly at its Mt Rawdon West Project, setting the stage for imminent drill testing backed by government funding.

PolyNovo has completed its pivotal US clinical trial report for NovoSorb BTM and adjusted its FDA Premarket Approval submission timeline to late 2026 to incorporate updated regulatory requirements and additional data.

ArborGen Holdings delivered its strongest revenue in five years with $68.2 million, driven by a 14% surge in Brazil and an 8% rise in adjusted EBITDA despite US market headwinds. The company’s focus on advanced genetics and operational efficiency underpins a confident FY27 outlook.

WAM Income Maximiser (ASX: WMX) has outpaced its benchmark with an 18.1% portfolio increase and exceeded its dividend target by delivering a 7.0% fully franked yield in its first year since April 2025.